Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause
Status:
COMPLETED
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
evaluate the efficacy of paroxetine in the management of vasomotor symptoms in patients with surgical menopause, in order to seek an alternative therapy to hormone therapy, which is associated with proinflammatory and procoagulant effects that increase the risk of thrombosis and is therefore contraindicated in people with diabetes mellitus, chronic arterial hypertension and patients with a history of thromboembolism